Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study

Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study

Abstract Background Leptomeningeal metastasis (LM) is a severe complication of advanced non-small cell lung cancer (NSCLC). This retrospective study aimed to investigate the potential use of osimertinib for preventing LM in patients with advanced epidermal growth factor receptor (EGFR)-mutated NSCLC...

Full description

Bibliographic Details
Main Authors:	Xia Wang, Jing Cai, Zhimin Zeng, Anwen Liu
Format:	Article
Language:	English
Published:	BMC 2021-07-01
Series:	BMC Cancer
Subjects:	Non-small-cell lung cancer Epidermal growth factor receptor Tyrosine kinase inhibitors Leptomeningeal metastasis Osimertinib Propensity score matching
Online Access:	https://doi.org/10.1186/s12885-021-08581-2

Similar Items

Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective study
by: Xia Wang, et al.
Published: (2021-04-01)

Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for leptomeningeal metastasis and successful treatment with osimertinib: A case report and literature review
by: Takeo Sakurai, et al.
Published: (2021-03-01)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
by: MuYun Peng, et al.
Published: (2020-09-01)

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
by: Lee CS, et al.
Published: (2021-08-01)

Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
by: Li H, et al.
Published: (2019-09-01)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
by: Svetlana V. Odintsova, et al.
Published: (2020-07-01)

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer
by: Tejas Patil, et al.
Published: (2020-04-01)

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
by: Izumi Sato, et al.
Published: (2020-08-01)

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells
by: Xiao-Yu Zhang, et al.
Published: (2016-09-01)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-08-01)

Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real‐world efficacy and safety in advanced/recurrent non‐small cell lung carcinoma
by: Takayuki Kishikawa, et al.
Published: (2020-04-01)

Successful Management of Neuroblastoma with Leptomeningeal Metastasis: An Interesting Case
by: Babak Abdolkarimi, et al.
Published: (2020-04-01)

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
by: Ruiting Lin, et al.
Published: (2021-09-01)

Research Advances in Leptomeningeal Metastasis from Non-small Cell Lung Cancer
by: LU Zhiqin, et al.
Published: (2020-12-01)

Hemidystonia as an Initial Manifestation of Leptomeningeal Metastasis
by: Hyun-Jung Jung, et al.
Published: (2009-10-01)

Papilledema: Could It Be an Important Clinical Sign of Leptomeningeal Metastasis?
by: Özge Arıcı Düz, et al.
Published: (2020-10-01)

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
by: Jing Liu, et al.
Published: (2019-07-01)

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
by: de Langen, A.J, et al.
Published: (2022)

Osimertinib for the first-line treatment of EGFR-positive non-small cell lung cancer
by: Elena V Reutova, et al.
Published: (2019-09-01)

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review
by: Li, S., et al.
Published: (2022)

Osimertinib making a breakthrough in lung cancer targeted therapy
by: Zhang H
Published: (2016-09-01)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
by: Akiko Takahashi, et al.
Published: (2018-10-01)

Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver Gene Positive Non-small Cell Lung Cancer
by: Zhiqin LU, et al.
Published: (2020-08-01)

Propensity-score matching: a clinician’s guide
by: Andrew D Althouse
Published: (2016-06-01)

Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI–IM–MS/MS Assay
by: Margaux Fresnais, et al.
Published: (2020-07-01)

Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
by: Tri Le, et al.
Published: (2019-03-01)

A propensity score matching study of laparoscopic and open hepatectomy in treatment of regional hepatolithiasis
by: WANG Xintuan, et al.
Published: (2018-03-01)

Osimertinib in NSCLC: Real-World Data From New Zealand
by: Yeojeong Jane So, MbChB, FRACP, et al.
Published: (2020-06-01)

Leptomeningeal metastasis from extracranial solid tumors
by: Dilip Harindran Vallathol, et al.
Published: (2020-01-01)

Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation—Positive Lung Cancer Cells
by: Paulina Skupin-Mrugalska, et al.
Published: (2020-09-01)

Evaluation of Two <i>EGFR</i> Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer
by: Jeong-Oh Kim, et al.
Published: (2020-03-01)

Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis
by: Hironori Uruga, et al.
Published: (2018-08-01)

Analysis of Clinicopathological Feature and Prognosis for  Leptomeningeal Metastasis in Non-small Cell Lung Cancer
by: Min ZHU, et al.
Published: (2016-08-01)

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy
by: K. A. Sarantseva, et al.
Published: (2020-12-01)

Late onset leptomeningeal and whole spine metastasis from supratentorial Glioblastoma multiforme: An uncommon manifestation of a common tumor
by: Divyam Sharma, et al.
Published: (2016-01-01)

Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival
by: Takashi Higuchi, et al.
Published: (2020-10-01)

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
by: Peng D, et al.
Published: (2021-02-01)

Re-evaluating Microfinance: Evidence from Propensity Score Matching
by: Cintina, I., et al.
Published: (2019)

Leptomeningeal Metastasis: The Role of Cerebrospinal Fluid Diagnostics
by: Lena Bönig, et al.
Published: (2019-08-01)

Impact of Entrepreneurship Education on Creativity: An Experience With Propensity Score Matching in Chile Impacto de la educación para el emprendimiento en la creatividad: Una experiencia en Chile con Propensity Score Matching
by: Francisco Olivos, et al.
Published: (2013-08-01)